Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma.

Bhargava R, Beriwal S, McManus K, Dabbs DJ.

Am J Clin Pathol. 2008 Nov;130(5):724-30. doi: 10.1309/AJCP3KFF1LTYWQIY.

PMID:
18854264
2.

Histopathologic variables predict Oncotype DX recurrence score.

Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R.

Mod Pathol. 2008 Oct;21(10):1255-61. doi: 10.1038/modpathol.2008.54.

3.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

4.

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.

Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2008 Sep;111(1):27-44. Epub 2007 Oct 6.

PMID:
17922188
5.

Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).

Lerma E, Peiro G, Ramón T, Fernandez S, Martinez D, Pons C, Muñoz F, Sabate JM, Alonso C, Ojeda B, Prat J, Barnadas A.

Mod Pathol. 2007 Nov;20(11):1200-7. Epub 2007 Sep 21.

6.

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.

Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, Kerkhoven RM, van Vliet MH, Wessels LF, Peterse JL, Berns A, Jonkers J.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6. Epub 2007 Jul 11.

7.

Molecular classification of breast tumors: toward improved diagnostics and treatments.

Sørlie T.

Methods Mol Biol. 2007;360:91-114. Review.

PMID:
17172726
8.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11.

PMID:
17159189
9.

Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.

Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, Hanby A.

Histopathology. 2006 Jul;49(1):22-34.

PMID:
16842243
10.

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.

JAMA. 2006 Jun 7;295(21):2492-502.

PMID:
16757721
11.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.

12.

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L.

Clin Cancer Res. 2005 Aug 15;11(16):5678-85.

13.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N.

N Engl J Med. 2004 Dec 30;351(27):2817-26. Epub 2004 Dec 10.

14.

Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.

Caly M, Genin P, Ghuzlan A A, Elie C, Fréneaux P, Klijanienko J, Rosty C, Sigal-Zafrani B, Vincent-Salomon A, Douggaz A, Zidane M, Sastre-Garau X.

Anticancer Res. 2004 Sep-Oct;24(5B):3283-8.

15.

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM.

Clin Cancer Res. 2004 Aug 15;10(16):5367-74.

16.
17.

Repeated observation of breast tumor subtypes in independent gene expression data sets.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23. Epub 2003 Jun 26.

18.

Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.

Spyratos F, Ferrero-Poüs M, Trassard M, Hacène K, Phillips E, Tubiana-Hulin M, Le Doussal V.

Cancer. 2002 Apr 15;94(8):2151-9. Review.

19.

Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison.

Lacroix M, Querton G, Hennebert P, Larsimont D, Leclercq G.

Breast Cancer Res Treat. 2001 Jun;67(3):263-71.

PMID:
11561772
20.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74.

Supplemental Content

Support Center